Share This Page
Suppliers and packagers for INTRALIPID 10%
✉ Email this page to a colleague
INTRALIPID 10%
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Fresenius | INTRALIPID 10% | soybean oil | INJECTABLE;INJECTION | 017643 | NDA | Baxter Healthcare CORP | 0338-0518-12 | 250 mL in 1 BAG (0338-0518-12) | 2014-12-12 |
| Fresenius | INTRALIPID 10% | soybean oil | INJECTABLE;INJECTION | 017643 | NDA | Baxter Healthcare CORP | 0338-0518-13 | 500 mL in 1 BAG (0338-0518-13) | 2014-12-12 |
| Fresenius | INTRALIPID 10% | soybean oil | INJECTABLE;INJECTION | 017643 | NDA | Baxter Healthcare CORP | 0338-0518-58 | 100 mL in 1 BAG (0338-0518-58) | 2014-12-12 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Intralipid 10%
Introduction
Intralipid 10% is a pivotal parenteral nutrition emulsion globally recognized for its lipid component in clinical settings. As a critical supply molecule in healthcare, ensuring reliable sourcing is essential for hospitals, pharmaceutical companies, and distribution channels. This article provides a comprehensive analysis of the key suppliers manufacturing Intralipid 10%, examining their market presence, manufacturing capabilities, regulatory compliance, and strategic positioning.
Overview of Intralipid 10%
Intralipid 10%, produced by Fresenius Kabi and other manufacturers, is an injectable fat emulsion used to provide essential fatty acids and calories in parenteral nutrition (PN). Its formulation comprises soybean oil, egg phospholipids, glycerin, and water for injection. Its consistent quality, stability, and safety profile necessitate strict manufacturing standards and regulatory approval, notably from entities such as the FDA, EMA, and other regional authorities.
Major Suppliers of Intralipid 10%
1. Fresenius Kabi
Market Leader and Global Supplier
Fresenius Kabi is the leading manufacturer and supplier of Intralipid 10%, owing to its extensive global manufacturing footprint and longstanding market presence. The company operates manufacturing facilities in multiple countries, including Germany, China, and the U.S., ensuring large-scale production and distribution.
Fresenius Kabi’s Intralipid 10% is widely used in hospitals and clinical settings worldwide, supported by robust regulatory approvals. The company's focus on quality control, with adherence to Good Manufacturing Practices (GMP), and comprehensive supply chain management underpin its dominant market position.
Manufacturing Capabilities and Compliance
Fresenius Kabi’s manufacturing facilities comply with ISO and GMP standards. The company invests heavily in R&D and quality assurance to maintain product purity, stability, and safety, crucial for parenteral nutrition products.
2. Baxter International
Alternative Global Supplier
Baxter International offers lipid emulsions for parenteral nutrition, including formulations comparable to Intralipid 10%. While Baxter’s primary focus is broader in IV therapies, their lipid emulsions serve as critical alternatives, especially in regions where Intralipid is unavailable or restricted.
Supply and Distribution
Baxter’s products are approved in multiple jurisdictions, with extensive distribution channels across North America, Europe, and emerging markets. Their manufacturing facilities are GMP-certified, and the company emphasizes product quality and safety.
3. Otsuka Pharmaceutical
Regional Supplier with Growing Presence
Otsuka Pharmaceutical manufactures lipid emulsions used in PN, mainly in Asian markets, notably Japan and Southeast Asia. Their infrastructure supports regional demand, with regulatory approval from local authorities such as the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
Limitations and Market Focus
While Otsuka supplies lipid emulsions akin to Intralipid 10%, their market share in Western markets remains limited, primarily serving regional hospitals and distributors.
4. Other Notable Manufacturers
-
Fresenius Kabi’s Competitors in the Regional Markets: Companies such as Vifor Pharma, APP Pharmaceuticals, and Aspen Pharmacare produce lipid emulsions that may serve as substitutes or adjuncts, though not exact equivalents.
-
Generic Manufacturers: Several emerging companies manufacture lipid emulsions to meet regional demands, often under local branding, with certifications ensuring compatibility with international standards.
Emerging Trends in Supplier Dynamics
Supply Chain Resilience and Geographical Diversification
Global disruptions, notably during the COVID-19 pandemic, underscored the importance of diversified sourcing. Companies increasingly seek multiple suppliers across different regions to mitigate risks associated with manufacturing halts or regulatory issues.
Regulatory Harmonization and Approvals
Suppliers must navigate complex regulatory landscapes, including approvals from agencies such as the FDA, EMA, and regional health authorities. Suppliers obtaining multiple international approvals significantly enhance their market access.
Quality Standards and Innovation
Amidst ongoing safety concerns, manufacturers emphasize enhanced manufacturing processes, traceability, and novel lipid formulations to improve bioavailability and reduce adverse effects.
Regulatory Considerations Affecting Suppliers
- Suppliers should maintain GMP certification and adhere to pharmacopeial standards (e.g., USP, EP).
- The safety profile depends on strict control of soybean oil purity, egg phospholipids, and contaminant levels.
- Variations in regional approvals impact suppliers’ ability to distribute Intralipid 10% globally.
Market Outlook and Supplier Strategy
Given the high clinical utilization rate, the supplier landscape is concentrated mainly around established pharmaceutical companies like Fresenius Kabi. The potential for new entrants hinges on regulatory approval, manufacturing scale, and quality assurance.
Healthcare providers and commissioners should prioritize sourcing from suppliers with proven regulatory compliance, scalable production capacity, and reliable logistics. Contracting with multiple suppliers may ensure uninterrupted supply, especially during global crises.
Key Takeaways
- Fresenius Kabi dominates the global Intralipid 10% market due to its extensive manufacturing infrastructure and regulatory approvals.
- Regional suppliers like Baxter and Otsuka provide alternatives tailored to specific markets, emphasizing the importance of diversified sourcing.
- Regulatory compliance and quality standards are critical factors influencing supplier credibility and product acceptance.
- Supply chain resilience has become a strategic priority, prompting diversification and contingency planning among healthcare providers.
- Future market dynamics will likely be shaped by innovation in lipid formulations, regulatory harmonization, and emerging regional players.
Frequently Asked Questions (FAQs)
1. What are the primary manufacturers of Intralipid 10% globally?
Fresenius Kabi is the leading manufacturer worldwide, with Baxter International, Otsuka Pharmaceutical, and regional producers also contributing to supply, especially in Asia and emerging markets.
2. How do regulatory approvals influence supplier selection for Intralipid 10%?
Regulatory approvals ensure product safety, quality, and consistent manufacturing standards, which are crucial for hospital procurement and supply chain stability.
3. Are there alternatives to Intralipid 10% available in the market?
Yes, several lipid emulsions from other manufacturers serve as alternatives, but they may vary in composition, approval status, and regional availability.
4. What factors are influencing the future supply of Intralipid 10%?
Regulatory changes, manufacturing capacity, supply chain disruptions, and innovation in lipid formulations are key factors shaping future supply.
5. How critical is supply chain diversification for hospitals sourcing Intralipid 10%?
It is vital to prevent shortages, particularly during global crises, ensuring that patient care remains uninterrupted.
References
[1] Fresenius Kabi. Intralipid 10% Product Information. 2022.
[2] Baxter International. Lipid Emulsion Portfolio. 2022.
[3] Otsuka Pharmaceutical. Parenteral Nutrition Lipid Emulsions Technical Data. 2021.
[4] U.S. Food and Drug Administration (FDA). Parenteral Lipid Emulsions Guidance. 2020.
[5] European Medicines Agency (EMA). Intralipid 10% Regulatory Status. 2021.
More… ↓
